Cargando…
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
Autores principales: | Tomelleri, Alessandro, Rinaldi, Emma, Campochiaro, Corrado, Picchio, Maria, Dagna, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891411/ https://www.ncbi.nlm.nih.gov/pubmed/35861513 http://dx.doi.org/10.1093/rheumatology/keac416 |
Ejemplares similares
-
Monkeypox in a patient with undifferentiated connective tissue disease
por: Clemente, Tommaso, et al.
Publicado: (2022) -
DWI scalp dot sign: superficial temporal artery restricted diffusion in giant cell arteritis
por: Taylor, Eleanor, et al.
Publicado: (2022) -
Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply
por: Wadström, Karin, et al.
Publicado: (2021) -
Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis: reply
por: Esen, Idil, et al.
Publicado: (2022) -
Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate: reply
por: Stamatis, Pavlos, et al.
Publicado: (2021)